表紙
市場調查報告書

疫苗佐劑的全球市場:2020年∼2024年

Vaccine Adjuvants Market by Application and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 918553
出版日期 內容資訊 英文 153 Pages
訂單完成後即時交付
價格
疫苗佐劑的全球市場:2020年∼2024年 Vaccine Adjuvants Market by Application and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年11月19日內容資訊: 英文 153 Pages
簡介

全球疫苗佐劑市場上,疫苗的佐劑使用增加,研究開發中的政府的輔助擴大,及疫苗接種計劃和提高疫苗利用的認知度的配合措施等成為成長促進因素,在預測期間內預計將以約11%的年複合成長率擴大。但,由於佐劑的副作用,佐劑固有的限制,及疫苗佐劑相關的安全性疑慮等要素,可能妨礙在預測期間內疫苗佐劑產業的成長。

本報告提供全球疫苗佐劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 親市場
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2019年∼2024年)
  • 感染疾病
  • 癌症
  • 其他的疾病
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 新疫苗佐劑的研究開發的增加
  • 奈米粒子佐劑的開發
  • 合作的增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Agenus Inc.
  • Avanti Polar Lipids Inc.
  • Croda International Plc
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • InvivoGen
  • Merck KGaA
  • OZ Biosciences SAS
  • SEPPIC SA
  • Vaxine Pty Ltd.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR40163

About this market

Technavio's vaccine adjuvants market analysis considers sales from infectious diseases, cancer, and other diseases. Our study also finds the sales of vaccine adjuvants in Asia, Europe, North America, and ROW. In 2019, the infectious diseases segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as R&D activities for the formulation of novel adjuvants to prevent the spread of infectious diseases will play a significant role in the infectious diseases segment to maintain its market position. Also, our global vaccine adjuvants market report looks at factors such as increasing use of adjuvants in vaccines, growing support of government in R&D, and initiatives to increase awareness of immunization programs and access to vaccines. However, side effects of adjuvants, inherent limitations of adjuvants, and safety concerns associated with vaccine adjuvants may hamper the growth of the vaccine adjuvants industry over the forecast period.

Overview

Initiatives to increase awareness of immunization programs and access to vaccines

Infants and children are prone to deadly diseases like hepatitis B, measles, and tetanus, which can cause serious harm. The lack of immunization awareness can lead to the propagation of such deadly diseases when simple measures could eradicate them completely. Therefore, raising awareness about immunization programs and increasing the access to vaccines is important. Awareness campaigns such as the World Immunization Week are celebrated at the end of April every year to raise awareness about how immunization and vaccination can fight against a host of diseases. Such initiatives will lead to the expansion of the global vaccine adjuvants market at a CAGR of almost 11% during the forecast period.

Development of nanoparticle adjuvants

Nanotechnology offers a multifunctional stage for the integration of desired adjuvant activities. Due to the high efficacy of vaccine adjuvants in potentiating a strong immune response in individuals, vendors are focusing on developing new-generation adjuvants to create a more potent antigen-specific response. Nanoparticles for antigen delivery can provide high bioavailability as well as constant and controlled-release profiles. Moreover, the immune-regulating activity of nanoparticles can further promote and shape cellular and humoral immune responses. Therefore, the combination of delivery functions and immunomodulatory effects of nanoparticles as adjuvants is expected to benefit the immune outcomes of vaccination largely. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global vaccine adjuvants market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of a few major players, the global vaccine adjuvants market is highly concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading vaccine adjuvants manufacturers, that include Agenus Inc., Avanti Polar Lipids Inc., Croda International Plc, CSL Ltd., GlaxoSmithKline Plc, InvivoGen, Merck KGaA, OZ Biosciences SAS, SEPPIC SA, and Vaxine Pty Ltd..

Also, the vaccine adjuvants market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market Outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Infectious diseases - Market size and forecast 2019-2024
  • Cancer - Market size and forecast 2019-2024
  • Other diseases - Market size and forecast 2019-2024
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increase in R&D of novel vaccine adjuvants
  • Development of nanoparticle adjuvants
  • Rising number of collaborations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agenus Inc.
  • Avanti Polar Lipids Inc.
  • Croda International Plc
  • CSL Ltd.
  • GlaxoSmithKline Plc
  • InvivoGen
  • Merck KGaA
  • OZ Biosciences SAS
  • SEPPIC SA
  • Vaxine Pty Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendor key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Application - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Infectious diseases - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Infectious diseases - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Cancer - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Cancer - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Other diseases - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 25: Other diseases - Year-over-year growth 2020-2024 (%)
  • Exhibit 26: Market opportunity by application
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2019-2024 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: Agenus Inc. - Vendor overview
  • Exhibit 51: Agenus Inc. - Business segments
  • Exhibit 52: Agenus Inc. - Organizational developments
  • Exhibit 53: Agenus Inc. - Geographic focus
  • Exhibit 54: Agenus Inc. - Key offerings
  • Exhibit 55: Agenus Inc. - Key customers
  • Exhibit 56: Avanti Polar Lipids Inc. - Vendor overview
  • Exhibit 57: Avanti Polar Lipids Inc. - Business segments
  • Exhibit 58: Avanti Polar Lipids Inc. - Organizational developments
  • Exhibit 59: Avanti Polar Lipids Inc. - Key offerings
  • Exhibit 60: Avanti Polar Lipids Inc. - Key customers
  • Exhibit 61: Croda International Plc - Vendor overview
  • Exhibit 62: Croda International Plc - Business segments
  • Exhibit 63: Croda International Plc - Organizational developments
  • Exhibit 64: Croda International Plc - Geographic focus
  • Exhibit 65: Croda International Plc - Segment focus
  • Exhibit 66: Croda International Plc - Key offerings
  • Exhibit 67: Croda International Plc - Key customers
  • Exhibit 68: CSL Ltd. - Vendor overview
  • Exhibit 69: CSL Ltd. - Business segments
  • Exhibit 70: CSL Ltd. - Organizational developments
  • Exhibit 71: CSL Ltd. - Geographic focus
  • Exhibit 72: CSL Ltd. - Segment focus
  • Exhibit 73: CSL Ltd. - Key offerings
  • Exhibit 74: CSL Ltd. - Key customers
  • Exhibit 75: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 76: GlaxoSmithKline Plc - Business segments
  • Exhibit 77: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 78: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 79: GlaxoSmithKline Plc - Segment focus
  • Exhibit 80: GlaxoSmithKline Plc - Key offerings
  • Exhibit 81: GlaxoSmithKline Plc - Key customers
  • Exhibit 82: InvivoGen - Vendor overview
  • Exhibit 83: InvivoGen - Product segments
  • Exhibit 84: InvivoGen - Key offerings
  • Exhibit 85: InvivoGen - Key customers
  • Exhibit 86: Merck KGaA - Vendor overview
  • Exhibit 87: Merck KGaA - Business segments
  • Exhibit 88: Merck KGaA - Organizational developments
  • Exhibit 89: Merck KGaA - Geographic focus
  • Exhibit 90: Merck KGaA - Segment focus
  • Exhibit 91: Merck KGaA - Key offerings
  • Exhibit 92: Merck KGaA - Key customers
  • Exhibit 93: OZ Biosciences SAS - Vendor overview
  • Exhibit 94: OZ Biosciences SAS - Product segments
  • Exhibit 95: OZ Biosciences SAS - Key offerings
  • Exhibit 96: OZ Biosciences SAS - Key customers
  • Exhibit 97: SEPPIC SA - Vendor overview
  • Exhibit 98: SEPPIC SA - Product segments
  • Exhibit 99: SEPPIC SA - Organizational developments
  • Exhibit 100: SEPPIC SA - Key offerings
  • Exhibit 101: SEPPIC SA - Key customers
  • Exhibit 102: Vaxine Pty Ltd. - Vendor overview
  • Exhibit 103: Vaxine Pty Ltd. - Business segments
  • Exhibit 104: Vaxine Pty Ltd. - Key offerings
  • Exhibit 105: Vaxine Pty Ltd. - Key customers
  • Exhibit 106: Validation techniques employed for market sizing
  • Exhibit 107: Definition of market positioning of vendors